News articles about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.6637361342847 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Esperion Therapeutics (NASDAQ:ESPR) traded up $0.23 on Wednesday, reaching $55.81. 346,518 shares of the company traded hands, compared to its average volume of 1,042,030. Esperion Therapeutics has a 1-year low of $10.30 and a 1-year high of $57.67.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same period last year, the company earned ($0.77) EPS. analysts expect that Esperion Therapeutics will post -7.21 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Esperion Therapeutics (ESPR) Stock Price” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/11/22/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-esperion-therapeutics-espr-stock-price.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
What are top analysts saying about Esperion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Esperion Therapeutics Inc. and related companies.